Adverse effects · Adults with a symptomatic necrotic tooth or localised acute apical abscess (no signs of spreading infection or systemic involvement)
1 finding from 1 review
Frequency of joint noise · People with temporomandibular disorders (TMD)
It is very uncertain whether occlusal splint changes frequency of joint noise compared with no treatment or placebo (non-occlusal or transparent-foil placebo… (very low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Quit at longest · smoking cessation in hospitalised patients
Pharmacotherapy plus counselling leads to higher quit at longest compared with no pharmacotherapy or placebo plus counselling (high certainty).
3 findings from 1 review
RR 1.33 [1.05, 1.67]
8 studies · 3838 participants
High
RR 1.11 [0.86, 1.43]
4 studies · 872 participants
Low
RR 1.29 [0.96, 1.75]
4 studies · 829 participants
Moderate
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
Time to next pulmonary exacerbation · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Hospital admissions · adults and children with cystic fibrosis
1 finding from 1 review
New acquisition of CF pathogens: PA · adults and children with cystic fibrosis
1 finding from 1 review
Need for additional antibiotics: participants needing extra IV antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
QoL · adults and children with cystic fibrosis
1 finding from 1 review
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment responsea · children and young people with JIA
Methotrexate may leads to higher treatment responsea(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Sustained clinically inactive diseasec · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain on motion · children and young people with JIA
1 finding from 1 review